Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry
To evaluate the impact of rituximab on patient-reported outcomes (PROs) in a US-based observational cohort of patients with rheumatoid arthritis (RA). Patients with active RA, prior exposure to ≥1 tumor necrosis factor inhibitor (TNFi) and who newly initiated rituximab were identified. Changes in PROs were assessed 1 year after rituximab initiation. PRO measures included Clinical Disease Activity Index (CDAI); patient global disease activity, pain and fatigue (visual analog score; 0–100); morning stiffness (hours); modified Health Assessment Questionnaire (mHAQ; 0–3); and EuroQoL EQ-5D. Of the 667 patients who newly initiated rituximab, baseline PRO and clinical measures indicated that patients were substantially impacted by their RA disease and quality of life; 54% of patients had high disease activity. One year after rituximab initiation, 49.0, 47.1, 49.8, and 23.2% of patients reported clinically meaningful improvements in patient global, pain, fatigue, and mHAQ, respectively. Morning stiffness and EuroQol EQ-5D domains improved in 48 and 19–32% of patients, respectively. These real-world registry data demonstrated that patients with long-standing, refractory RA experienced improvements in PROs 1 year after initiating rituximab.
KeywordsBiologics Patient-reported outcomes Rheumatoid arthritis Rituximab
Patients with rheumatoid arthritis (RA) often experience reduced health-related quality of life (HRQOL), including disability and RA-related comorbidities [1, 2]. The goals of treatment in RA are to achieve low disease activity (LDA) or remission and to improve HRQOL.
Patient-reported outcomes (PROs) include HRQOL indices, such as the ability to perform day-to-day tasks, emotional health, and the degree of pain and discomfort. PROs are increasingly being recognized as important measures in determining response to therapy in patients with RA [3, 4, 5].
Rituximab is a monoclonal antibody that targets and depletes CD20+ B cells and, in combination with methotrexate, is approved for the treatment of RA in patients who have had an inadequate response to ≥1 tumor necrosis factor inhibitor (TNFi). Limited data exist on the effect of rituximab on PROs in real-world clinical settings. This study examined the impact of rituximab on PROs in a US observational cohort of patients with RA.
The Corrona RA Registry is an independent, prospective, observational cohort of patients with RA [6, 7]. Patients are recruited from 169 private and academic practice sites across 40 states in the USA, with 656 participating rheumatologists. As of June 20, 2016, data on 43,099 patients with RA have been collected. The protocol was approved by the New England institutional review board (IRB; #120160610) and the local IRBs of participating academic sites. Registration number: NCT01402661.
Study analysis population
Adult patients with RA who initiated rituximab for the first time within Corrona from March 2006 to September 2015 were identified. Eligible patients had available PRO measurements at baseline (around the time of rituximab initiation) and 1 year (9–15 months) after rituximab initiation. All patients had previously received ≥1 TNFi and had low, moderate, or high disease activity based on Clinical Disease Activity Index (CDAI), defined as CDAI >2.8.
Assessments and outcomes
CDAI was assessed at 1 year and evaluated by the median change from baseline and by the proportion of patients achieving LDA/remission (CDAI ≤10). PROs were assessed at 1 year and included the median change from baseline and the proportion of patients reporting minimum clinically important differences (MCIDs; defined as improvement of ≥10) in patient global assessment of disease, pain, and fatigue (0–100 on a visual analog scale) ; improvement in morning stiffness (duration in hours); proportion of patients achieving a clinically meaningful improvement in modified Health Assessment Questionnaire (mHAQ), defined as a decrease of >0.25 from baseline in the mHAQ score ; and improvement in the EuroQol EQ-5D overall health status index, which records patient-reported HRQOL across five domains (walking, self-care, usual activities, pain/discomfort, and anxiety/depression). EuroQol EQ-5D results are examined using a summary index (0–1) or by individual evaluation of each domain . Improvement in EQ-5D domains was defined as the proportion of patients with any improvement or resolution of impairment among patients who reported impairment at baseline.
PROs and CDAI were evaluated for both the overall cohort and in patient populations stratified by number of prior TNFis (1 or ≥2 prior TNFis). For patients with ≥2 visits within the time frame for the 12-month visit, the visit closest to 12 months was used.
Comparisons between the 1 and ≥2 prior TNFi groups were performed using χ2, t, or nonparametric equality-of-medians tests, as appropriate. Responses for the outcome measures were available for >95% of patients during the time when the variables were part of the data collection process; patients with missing data were excluded from outcome analyses.
Patient demographics and baseline PROs
Baseline patient demographics, clinical characteristics, disease activity, and PRO measures
N = 667
1 Prior TNFi
n = 284
≥2 Prior TNFis
n = 383
Demographics and clinical characteristics
Age, median (IQR), years
Female, n (%)
White, n (%)
Duration of RA, median (IQR), years [n]
History of cardiovascular disease, n (%)
History of diabetes, n (%)
History of hyperlipidemia, n/N (%)
RF seropositive, n/N (%)
No. of prior nonbiologic DMARDs, median (IQR)
No. of prior non-TNFi biologics, %
CDAI score, n (%)
Low (>2.8 and ≤10)
Moderate (>10 and ≤22)
HRQOL measures, median (IQR) [n]
Patient global assessment (0–100)
Patient pain (0–100)
Patient fatigue (0–100)
mHAQ score (0–3)
Morning stiffness, hours
Patients were substantially impacted by their RA at baseline. Overall, baseline median (IQR) scores for patient global assessment, pain, and fatigue were 40 (25–60), 60 (31–75), and 65 (40–80) mm, respectively (Table 1). The baseline median mHAQ score was 0.6 (IQR, 0.3–1), and patients reported a median of 1 (IQR, 0.5–2) hour of morning stiffness. Most patients reported at least some problems in the EQ-5D categories of walking (75.7%), usual activities (81.1%), and pain/discomfort (95.8%). Almost one-half of all patients reported at least some problems in self-care (48.6%) and anxiety/depression (49.0%). Baseline PRO scores were mostly similar between patients who had received 1 or ≥2 prior TNFis, with the exception of fatigue and morning stiffness.
Overall, 78.9% of patients persisted on rituximab through 1 year, whereas 21.1% switched to another biologic before 1 year. Among all patients, 63.3% received rituximab retreatment and did not switch to another biologic, and 15.6% did not receive rituximab retreatment but also did not switch to another biologic (Supplemental Table 1).
Improvement in CDAI and PROs 1 year after rituximab initiation
The median improvement in CDAI from baseline to 1 year was 8 (IQR, 17.8); results were similar between patients with 1 or ≥2 prior TNFis. Overall, 30.4% of patients achieved CDAI LDA/remission (CDAI ≤10) at 1 year. A significantly higher proportion of patients with 1 prior TNFi achieved CDAI LDA/remission than patients with ≥2 prior TNFis (37.7 vs 25.1%, respectively; P < 0.001).
In this real-world cohort of patients with long-standing, refractory RA with active disease and prior TNFi exposure, improvements were reported in all PROs 1 year after initiation of rituximab. The overall median duration of RA was 13 years; whereas all patients had prior TNFi exposure, almost one-half (47.5%) had also received ≥2 prior non-TNFi biologics. At baseline, 88% of patients had moderate or high disease activity based on CDAI, and patients were substantially impacted by their RA: most patients reported problems with walking, usual activities, and pain/discomfort, and almost one-half reported problems with self-care and anxiety/depression. One year after initiation of rituximab, 30% of patients achieved LDA/remission (CDAI ≤10), and 49.0, 47.1, and 49.8% of patients achieved MCIDs in patient global, pain, and fatigue, respectively. Among patients who had reported problems at baseline, 11–32% reported no problems in walking, self-care, usual activities, pain/discomfort, and anxiety/depression at 1 year.
Clinical trials have also reported improvements in PROs among patients with comparable disease duration and prior use of TNFis; however, these studies reported different PRO measures, including HAQ—disability index, Functional Assessment of Chronic Illness Therapy—Fatigue, and Short Form 36, 6 months after initiation of rituximab, limiting the ability to directly compare our results with clinical trial results [11, 12]. Real-world data on PROs in rituximab-treated patients with RA are limited. A recent open-label study of rituximab in patients with long-standing RA showed that improvement in PROs occurred early after initiation of rituximab, plateaued at 12 weeks, and persisted through 24 weeks . Although our study did not include PRO measures at time points of <1 year, our findings suggest that the improvement in PROs after rituximab initiation extends through 1 year.
This analysis is among the first to describe patient real-world experience with rituximab treatment 1 year after initiation. Patients in this observational cohort were treated and followed consistent with routine care rather than based on a mandated treatment protocol or visit schedule. Most patients (≈80%) persisted with rituximab through 1 year. However, because the follow-up period for this analysis was limited to 1 year, the long-term effect of rituximab, with or without retreatment, on PROs could not be ascertained.
In conclusion, these results suggest that treatment with rituximab can improve HRQOL in addition to controlling or improving underlying disease in patients with long-standing RA previously treated with TNFis.
Support for third-party writing assistance, furnished by Ellen Mercado, PhD, of Health Interactions, Inc., was provided by Genentech, Inc./F. Hoffmann-La Roche, Ltd.
Compliance with ethical standards
This study was sponsored by Corrona, LLC. Corrona, LLC has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Crescendo, Eli Lilly, Genentech, GSK, Horizon Pharma, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer, Roche, and UCB.
Conflict of interest
LRH is an employee of the University of Massachusetts Medical School and is a consultant for Bristol-Myers Squibb. AJ, JB, and SZ are employees of Genentech. CK is an employee of Corrona, LLC. YL declares no conflicts of interest. JDG is an employee and shareholder of Corrona, LLC, and a consultant for Genentech, Janssen, Novartis, Pfizer, and Eli Lilly. JMK is an employee and shareholder of Corrona, LLC, and a consultant for AbbVie, Amgen, Bristol-Myers Squibb, Genentech, GSK, Eli Lilly, Pfizer, Regeneron, and Sanofi.
- 6.Curtis JR, Chen L, Bharat A, Delzell E, Greenberg JD, Harrold L, Kremer J, Setoguchi S, Solomon DH, Xie F, Yun H (2014) Linkage of a de-identified United States rheumatoid arthritis registry with administrative data to facilitate comparative effectiveness research. Arthritis Care Res (Hoboken) 66:1790–1798. doi:10.1002/acr.22377 CrossRefGoogle Scholar
- 9.Wolfe F, Pincus T (1999) Listening to the patient: a practical guide to self-report questionnaires in clinical care. Arthritis Rheum 42:1797–1808. doi:10.1002/1529-0131(199909)42:9<1797::AID-ANR2>3.0.CO;2-Q CrossRefPubMedGoogle Scholar
- 11.Keystone E, Burmester GR, Furie R, Loveless JE, Emery P, Kremer J, Tak PP, Broder MS, Yu E, Cravets M, Magrini F, Jost F (2008) Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 59:785–793. doi:10.1002/art.23715 CrossRefPubMedGoogle Scholar
- 12.Mease PJ, Revicki DA, Szechinski J, Greenwald M, Kivitz A, Barile-Fabris L, Kalsi J, Eames J, Leirisalo-Repo M (2008) Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: results of the dose-ranging assessment: international clinical evaluation of rituximab in rheumatoid arthritis (DANCER) trial. J Rheumatol 35:20–30PubMedGoogle Scholar
- 13.Gossec L, Danré A, Combe B, Le Loët X, Tebib J, Sibilia J, Mariette X, Dougados M. (2015) Improvement in patient-reported outcomes after rituximab in rheumatoid arthritis patients: an open-label assessment of 175 patients. Joint Bone Spine 82:451-454. doi: 0.1016/j.jbspin.2015.02.007Google Scholar
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.